# Eczema (Atopic Dermatitis): A Complete Patient Guide

> Eczema is a chronic inflammatory skin condition causing intense itch, dryness.

*Atopic dermatitis (eczema) is the world's most common inflammatory skin disease, affecting roughly 220 million people globally — up to 20% of children and 10% of adults. It stems from a defective epidermal barrier (often due to filaggrin gene mutations), Th2-skewed immune dysregulation, and Staphylococcus aureus colonization. Treatment follows a step-wise ladder: daily emollients plus trigger avoidance form the foundation; topical corticosteroids and calcineurin inhibitors manage flares; biologics (dupilumab) and JAK inhibitors are approved for moderate-to-severe disease.*

- Canonical: https://beautycomparison.com/eczema-guide
- Reviewed: 2026-06-20
- Publisher: Beauty Comparison (Beauty Comparison Editorial) — independent, brand-neutral

## Key takeaways
- Eczema is not caused by poor hygiene — it arises from a genetic skin barrier defect (often filaggrin mutations) combined with an overactive Th2 immune response, allowing allergens and irritants to penetrate and trigger inflammation.
- Staphylococcus aureus colonizes the skin of over 90% of people with atopic dermatitis and actively worsens flares by producing toxins that amplify the Th2 immune cascade.
- Emollients are the cornerstone of eczema management: applied immediately after bathing, they reduce transepidermal water loss, lower flare frequency, and decrease the need for medicated treatments.
- Topical corticosteroids remain first-line for flares, but the face and skin folds should use low-potency formulations or topical calcineurin inhibitors (tacrolimus, pimecrolimus) to avoid atrophy.
- Dupilumab — a biologic that blocks IL-4 and IL-13 signaling — is FDA-approved from age 6 months and has transformed moderate-to-severe eczema management, with meta-analyses showing significant EASI score reductions versus placebo.
- Most children see improvement as they age; a meta-analysis found only 5% had persistent disease after 20 years, though adult-onset eczema is increasingly recognized and often requires ongoing management.

## What Is Eczema?

Eczema is an umbrella term for a group of chronic inflammatory skin conditions that cause dryness, intense itching, and rash. The most common form — and the focus of this guide — is **atopic dermatitis (AD)**, accounting for the vast majority of eczema diagnoses worldwide.

Atopic dermatitis is not a cosmetic problem or a hygiene issue. It is a complex, genetically influenced disease involving a defective epidermal barrier and a dysregulated immune system. The word "atopic" refers to the tendency to develop allergic conditions — many people with eczema also have asthma, allergic rhinitis (hay fever), or food allergies, a cluster known as the atopic march.

---

## How Common Is Eczema?

Eczema ranks as the **leading nonfatal skin disease burden worldwide**, affecting approximately 220–230 million people globally. Key prevalence data:

- **Children:** Up to 20% are affected, with 45% of cases presenting within the first 6 months of life and 80–90% developing before age 5.
- **Adults:** Approximately 10% of adults have atopic dermatitis; around 25% of adult cases develop for the first time in adulthood.
- **Trend:** Prevalence has increased two- to threefold in developed countries over recent decades, suggesting a role for environmental and lifestyle factors beyond genetics alone.
- **Prognosis:** Many children improve substantially as they age. A systematic review found only around 5% of patients had persistent eczema 20 years after diagnosis, though relapse in adulthood is common.

---

## The Biology of Eczema: Why It Happens

Understanding the cause matters because it shapes every aspect of management.

### 1. Skin Barrier Dysfunction

The outermost layer of the skin — the stratum corneum — normally acts as a selective barrier, keeping moisture in and irritants, allergens, and microbes out. In people with atopic dermatitis, this barrier is structurally defective.

The strongest genetic risk factor is **loss-of-function mutations in the filaggrin (FLG) gene**. Filaggrin is a structural protein essential to the [skin barrier](/skin-barrier-repair-guide). When it is deficient or absent:
- The skin loses water rapidly (**increased transepidermal water loss, TEWL**)
- [Ceramide](/ceramides-skin-barrier) and lipid content in the stratum corneum drops
- Skin pH rises, activating inflammatory proteases
- Allergens, irritants, and microbes penetrate more easily

FLG mutations also correlate with earlier onset, greater severity, persistent disease into adulthood, and a higher risk of IgE-mediated sensitization to foods and aeroallergens.

### 2. Immune Dysregulation

Once the barrier is breached, the immune system responds — and in people with atopic dermatitis, it responds in an exaggerated, Th2-skewed way.

**In acute eczema lesions:** Th2 cells dominate, releasing cytokines including IL-4, IL-5, IL-13, and IL-31. IL-4 and IL-13 suppress the production of skin barrier proteins, creating a destructive feedback loop — the inflammation worsens the barrier, the impaired barrier perpetuates inflammation. IL-31 is the primary driver of itch.

**In chronic eczema lesions:** The response shifts toward a mixed Th2/Th1 pattern, producing thickened, lichenified (leathery) skin.

This cytokine profile is the target of modern biologics: dupilumab blocks both IL-4 and IL-13 via the shared IL-4Rα receptor.

### 3. Staphylococcus Aureus Colonization

*S. aureus* colonizes the skin of **over 90% of people with atopic dermatitis**, compared with about 5–30% of healthy individuals. This is not a coincidence. The impaired barrier provides easy entry; the alkaline skin pH and reduced antimicrobial peptide production allow colonization to flourish. *S. aureus* then releases toxins (superantigens) that directly activate T cells, amplify the Th2 response, and worsen barrier dysfunction — another vicious cycle.

---

## Symptoms of Atopic Dermatitis

The hallmark symptoms are:

- **Intense pruritus (itch):** The most distinctive feature. Itch in eczema is driven by IL-31 acting on itch neurons. It is often worse at night and can severely disrupt sleep.
- **Dry skin:** Persistent throughout the body, not only in affected areas.
- **Erythematous (red) patches and plaques:** In darker skin tones, eczema may appear brown, purple, or gray rather than red — a common reason for delayed diagnosis.
- **Weeping and crusting:** In acute or infected flares, lesions may ooze serous fluid or form golden crusts (suggesting S. aureus secondary infection).
- **Lichenification:** Chronic scratching produces thickened, leathery skin with accentuated skin lines.

### How Eczema Looks by Age

Eczema distribution is characteristically age-dependent:

| Age | Typical Distribution |
|---|---|
| Infants (< 2 years) | Face (cheeks, forehead), scalp, outer arms and legs |
| Children (2–12 years) | Flexural creases — inner elbows, behind knees, wrists, ankles |
| Adults | Flexures, hands, neck, face, or diffuse involvement; hand eczema common |

---

## Common Triggers

Eczema is a chronic relapsing condition. Triggers do not cause eczema but provoke flares in already-susceptible skin. Common triggers include:

- **Irritants:** Harsh soaps, detergents, fragrances, solvents, prolonged water exposure
- **Allergens (contact):** Nickel, preservatives (formaldehyde releasers, methylisothiazolinone), rubber additives, certain cosmetic ingredients
- **Aeroallergens:** House dust mite, pet dander, pollen (in some patients)
- **Skin infections:** *S. aureus* (most common), herpes simplex virus (eczema herpeticum — a medical emergency)
- **Environmental:** Cold, dry weather; low humidity; excessive sweating
- **Stress:** Does not cause eczema but triggers or worsens flares via neuroimmune pathways
- **Wool and synthetic fabrics:** Mechanical irritation on sensitized skin
- **Food:** Relevant primarily in infants and young children with IgE-mediated sensitization (egg, milk, peanut, wheat, soy). In adults, food allergy rarely drives eczema flares and elimination diets should not be pursued without allergy testing.

---

## Diagnosing Eczema

Atopic dermatitis is a **clinical diagnosis** — there is no single definitive test. Clinicians apply the **Hanifin-Rajka criteria**, which requires 3 of 4 major features:
1. Pruritus (itching)
2. Typical morphology and age-appropriate distribution
3. Chronic or chronically relapsing course
4. Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)

Additional tests may be used in specific circumstances:
- **IgE testing (specific allergen panels):** May identify allergic sensitizations, though sensitization does not always indicate a clinically relevant trigger
- **Patch testing:** Considered when contact allergy is suspected in treatment-resistant cases
- **Skin biopsy:** Not routine, but useful when the diagnosis is genuinely uncertain

---

## The Treatment Ladder

Atopic dermatitis treatment follows a step-wise escalation matched to disease severity. All patients should have the foundational skincare steps in place regardless of which step of treatment they are on.

### Foundation: Emollients and Trigger Avoidance

**Emollients (moisturizers) are the cornerstone of eczema care.** Applied daily — ideally within 3 minutes of bathing while the skin is still slightly damp — they reduce TEWL, restore barrier lipids, and decrease inflammation. The AAD's updated guidelines include moisturizers among their strong recommendations.

Clinical evidence supports this: a randomized trial published in *PLOS Medicine* found that consistent emollient use from early infancy delayed or reduced the risk of eczema development in high-risk infants. For established eczema, daily emollient use reduces flare frequency, lowers steroid consumption, and improves patient-reported outcomes.

**What kind of emollient?** Thicker vehicles (ointments, creams) outperform thin lotions. Look for fragrance-free, dye-free products with ceramides, petrolatum, glycerin, or colloidal oatmeal. Fragrances are a leading contact sensitizer in eczema skin and should be avoided.

See the full guide on [/best-moisturizer-eczema](/best-moisturizer-eczema) for product selection criteria.

### Step 1: Topical Corticosteroids (TCS) — For Flares

Topical corticosteroids remain the **first-line pharmacological treatment for eczema flares**. They suppress inflammation rapidly and reduce itch within days.

TCS are classified by potency (Groups I–VII in the US; Groups 1–7 in the UK):
- **Mild potency** (e.g., hydrocortisone 1%): Face, eyelids, skin folds, infants
- **Moderate potency** (e.g., triamcinolone 0.1%): Trunk and limbs in children and adults
- **High/very high potency** (e.g., clobetasol 0.05%): Thick plaques on hands, feet, or scalp; short-term use only

**Key principles:**
- Apply once or twice daily during a flare; do not use continuously long-term
- Use the fingertip unit (FTU) method for dosing guidance — one FTU covers an area roughly double the size of an adult hand
- Avoid high-potency steroids on the face, skin folds, and in infants
- Proactive maintenance therapy (twice-weekly application to formerly affected areas) reduces relapse frequency — this approach is well-supported in clinical evidence

Side effects of prolonged TCS use include skin atrophy, telangiectasia, and striae. These risks are concentration- and duration-dependent and largely avoidable with appropriate use.

### Step 2: Topical Calcineurin Inhibitors (TCIs)

Tacrolimus ointment (0.03% and 0.1%) and pimecrolimus cream (1%) are **steroid-sparing anti-inflammatory options**. They are particularly valuable for:
- The **face, eyelids, and skin folds** — areas at highest risk of steroid atrophy
- Long-term maintenance therapy
- Patients who have had steroid-related side effects

A 2023 Cochrane review of 20 randomized controlled trials (n=5,885) found tacrolimus 0.1% superior to low-potency corticosteroids and comparable to moderate-potency TCS. The most common side effect is a burning sensation on first use, which is mild and transient.

The FDA's black-box warning about a theoretical malignancy risk was placed in 2005 based on animal data and a mechanistic concern — a prospective 10-year study of 7,954 children using tacrolimus found no cases of lymphoma.

### Step 3: Newer Topical Agents

For patients requiring additional options beyond TCS and TCIs, several newer topicals are now available:
- **Crisaborole 2% ointment** (PDE4 inhibitor): Approved for mild-to-moderate AD from age 3 months; reduces inflammation and itch
- **Roflumilast 0.15% cream** (PDE4 inhibitor): Approved from age 6, providing rapid itch relief
- **Ruxolitinib 1.5% cream** (JAK inhibitor): Approved from age 12 for mild-to-moderate AD; short-term use only; acts rapidly on itch

### Step 4: Phototherapy

**Narrowband UVB (NB-UVB) phototherapy** is an effective and well-tolerated option for moderate-to-severe eczema inadequately controlled by topicals. It is delivered 2–3 times per week in a dermatologist's office or home phototherapy unit. It suppresses the Th2 immune response and reduces itch and inflammation. It requires a commitment to frequent clinic visits and is not suitable for all patients (photosensitizing medications, pregnancy).

### Step 5: Systemic and Biologic Treatments

When topical therapy and phototherapy are insufficient for moderate-to-severe disease, systemic treatments are the next step:

**Dupilumab (Dupixent)** — the most significant advance in eczema treatment in decades. A fully human monoclonal antibody that blocks both IL-4 and IL-13 by binding to the shared IL-4Rα receptor. FDA-approved for atopic dermatitis from age 6 months.
- A meta-analysis of randomized controlled trials (PMC, 2022) found dupilumab significantly improved EASI scores (SMD −10.90), percentage BSA affected, pruritus scores, and dermatology quality of life index scores versus placebo (all p < 0.001)
- Does not suppress the broad immune system — no requirement for routine blood monitoring

**IL-13 inhibitors:**
- **Tralokinumab** (Adbry) — approved ages 12+ for moderate-to-severe AD
- **Lebrikizumab** — approved ages 12+ for moderate-to-severe AD

**JAK inhibitors (oral):**
- **Upadacitinib** (Rinvoq) and **abrocitinib** (Cibinqo) — approved from age 12; act rapidly but carry a class warning about thrombosis, serious infections, and cardiovascular events; require careful patient selection and monitoring

**Older immunosuppressants** (cyclosporine, methotrexate, mycophenolate) have been used for decades and remain options where biologics are unavailable or unaffordable, but carry a less favorable long-term safety profile.

---

## Eczema in Skin of Color

Atopic dermatitis presents differently in darker skin tones and this difference contributes to delayed and missed diagnoses. Key considerations:
- Erythema may appear purple, brown, or gray rather than red, making clinical assessment more challenging
- Post-inflammatory hyperpigmentation and hypopigmentation after flares are more prominent and can persist for months
- Lichenification (skin thickening) tends to be more pronounced
- Perifollicular accentuation (bumpy texture around hair follicles) is a common presentation pattern

---

## Mental Health and Quality of Life

Eczema is not a superficial condition. The chronic itch-scratch cycle, sleep disruption, and visible skin changes impose a significant psychological burden:
- Studies consistently find higher rates of anxiety, depression, and impaired social functioning in people with moderate-to-severe eczema compared to the general population
- Children with eczema are at increased risk of bullying
- The condition affects school performance, work productivity, and relationships

Mental health support should be part of comprehensive eczema care, not an afterthought.

---

## When to See a Dermatologist

Self-management with emollients and OTC hydrocortisone is appropriate for mild eczema. See a board-certified dermatologist if:

- Eczema is moderate, severe, or covering large body areas
- OTC measures have failed to control symptoms after 4–6 weeks
- Eczema is significantly disrupting sleep or daily activities
- Skin appears infected (golden crusting, warmth, rapidly spreading redness, fever)
- You notice painful blisters with a "punched-out" appearance — this may be eczema herpeticum (HSV infection), a medical emergency requiring urgent antiviral treatment
- You are considering pregnancy or are pregnant and currently using prescription treatments
- Mental health is significantly impacted

Early specialist involvement reduces long-term skin damage, prevents unnecessary scarring, and improves quality of life.

## FAQ
**Is eczema treatment still improving in 2026?**

Yes — significantly. The biologic era has transformed moderate-to-severe eczema management. Dupilumab (approved from age 6 months) consistently achieves major reductions in EASI scores in randomized trials. Tralokinumab and lebrikizumab (IL-13 inhibitors) offer additional options from age 12. Oral JAK inhibitors (upadacitinib, abrocitinib) provide rapid itch control. Newer topical agents including roflumilast and ruxolitinib cream expand the toolkit for mild-to-moderate disease. Research into the microbiome, filaggrin restoration, and prevention via early emollient use continues to advance understanding.

**Is eczema contagious?**

No. Eczema is not contagious and cannot be spread from person to person. It is an internal condition driven by genetics and immune dysregulation, not an infection. The secondary bacterial infections that sometimes complicate eczema (S. aureus) could theoretically be spread, but the eczema itself is not transmissible.

**Will my child's eczema go away?**

Many children see substantial improvement as they age. A systematic meta-analysis found that approximately 5% of patients had persistent eczema 20 years after diagnosis. However, eczema does not disappear for everyone — it can persist or recur in adulthood, particularly on the hands with occupational exposures. Effective early management and trigger avoidance give the best foundation for long-term control.

**What is the fastest way to calm an eczema flare?**

A short course of topical corticosteroid appropriate to the affected body site is the most evidence-backed option for rapid flare control. Apply immediately after a lukewarm shower, on slightly damp skin. Add a thick, fragrance-free emollient on top. Avoid known triggers. If the skin appears infected (golden crusting, warmth), contact your doctor — a bacterial infection requires antimicrobial treatment alongside topical anti-inflammatories. Do not use high-potency steroids on the face without clinician guidance.

**Can diet affect eczema?**

In infants and young children, IgE-mediated food allergy (egg, cow's milk, peanut, wheat, soy) can drive eczema flares and is worth investigating with allergy testing when suspected. In adults, the evidence for food as a primary eczema trigger is weaker. Broad elimination diets are not recommended without formal allergy testing and dietitian involvement — they can cause nutritional deficiencies and may not improve eczema at all. If you suspect a food trigger, work with an allergist rather than eliminating foods arbitrarily.

**What is the difference between eczema and contact dermatitis?**

Contact dermatitis is a skin reaction to direct contact with an external substance, and it is a type of eczema. Allergic contact dermatitis (ACD) involves a delayed immune (Type IV) reaction to a specific allergen — nickel, preservatives, rubber, fragrance — and requires prior sensitization. Irritant contact dermatitis (ICD) is a non-immune reaction to direct chemical damage from irritants like harsh cleansers or solvents. Atopic dermatitis is a systemic condition driven by genetics and the immune system, and it is not caused by a specific external substance, though contact allergens can worsen it.

## When to see a professional
Consult a dermatologist if eczema is moderate or severe, covers large body areas, significantly disrupts sleep or daily life, fails to respond to OTC emollients and mild hydrocortisone after 4–6 weeks, shows signs of secondary infection (golden crusting, rapidly spreading redness, warmth, fever), or if you notice painful blisters suggesting eczema herpeticum (a medical emergency requiring urgent antiviral treatment). Pregnant patients currently using prescription eczema treatments should also seek dermatologist review. Children with eczema and suspected food allergies should be evaluated by an allergist. Seek care promptly — untreated moderate-to-severe eczema causes significant morbidity and early specialist involvement substantially improves outcomes.

## Sources
- Atopic Dermatitis: A Review of Diagnosis and Treatment — PubMed Central / NIH (2024-12-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC11627575/
- Atopic Dermatitis — StatPearls (NCBI Bookshelf) — StatPearls / National Center for Biotechnology Information (2024-01-01): https://www.ncbi.nlm.nih.gov/books/NBK448071/
- American Academy of Dermatology: Updated Atopic Dermatitis Guidelines for Topical Therapies — American Academy of Dermatology (AAD) (2023-01-01): https://www.aad.org/news/updated-atopic-dermatitis-guidelines-topical-therapies
- Eczema types: Atopic dermatitis diagnosis and treatment — American Academy of Dermatology (AAD): https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/treatment
- Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials — PubMed Central / NIH (2022-07-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC9326918/
- From the Cochrane Library: Topical Tacrolimus for Atopic Dermatitis — PubMed Central / Cochrane Library (2023-07-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC10334957/
- Skin barrier in atopic dermatitis: beyond filaggrin — PubMed Central / NIH (2016-04-01): https://pmc.ncbi.nlm.nih.gov/articles/PMC4999106/

_Health information, not medical advice._